Biological
allogeneic CAR-T
allogeneic CAR-T is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph early_phase_1
1
33%
Ph phase_1
2
67%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Not yet recruiting2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 12 (66.7%)
Trials by Status
not_yet_recruiting267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingearly_phase_1
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
NCT07129642
not_yet_recruitingphase_1
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT07113496
not_yet_recruitingphase_1
RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies
NCT07105735
Clinical Trials (3)
Showing 3 of 3 trials
NCT07129642Early Phase 1
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
NCT07113496Phase 1
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT07105735Phase 1
RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3